Posted by Michael Wonder on 23 Nov 2015
Novartis receives FDA regular approval for Tafinlar + Mekinist to treat aggressive form of melanoma based on long-term survival data
20 November 2015 - This is the first targeted therapy combination demonstrating more than two years overall survival in patients with the most aggressive form of skin cancer.
For more details, go to: http://www.multivu.com/players/English/7694551-novartis-fda-approval-tafinlar-mekinist/
